Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Geneva Risk Score for Venous Thromboembolism (VTE) Prophylaxis

    Predicts need for VTE prophylaxis in admitted patients.
    Favorite

    INSTRUCTIONS

    Note: this score is different from the Geneva Score (Revised) for PE, which diagnoses PE in patients presenting with relevant signs and symptoms.

    Why Use

    Wide variation exists in the proportion of patients in a given institution who are given VTE prophylaxis (29-89% range in one study, Chopard 2006). This score can help institutions and individuals make evidence-based decisions on who is at sufficiently low risk for VTE so as to avoid unnecessary prophylaxis.

    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +2
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    As with any clinical decision tool, use your judgment when making therapeutic decisions. 

    Formula

    Addition of the selected points:

    Variable

    Points

    Cardiac failure

    2

    Respiratory failure

    2

    Recent stroke (<3 months ago)

    2

    Recent myocardial infarction (<4 weeks ago)

    2

    Acute infectious disease (including sepsis)

    2

    Acute rheumatic disease

    2

    Active malignancy

    2

    Myeloproliferative syndrome

    2

    Nephrotic syndrome

    2

    History of venous thromboembolism

    2

    Known hypercoagulable state

    2

    Immobilization (<30 min walking per day) for ≥3 days

    1

    Recent travel for >6 hrs

    1

    Age >60 years

    1

    Obesity (BMI >30)

    1

    Chronic venous insufficiency

    1

    Pregnancy

    1

    Hormonal therapy (contraceptive or replacement therapy)

    1

    Dehydration

    1

    Facts & Figures

    Interpretation:

    Geneva Score for VTE Prophylaxis

    Risk group

    Risk of VTE*

    Recommendation

    <3

    Low

    0.6%

    No VTE prophylaxis indicated

    ≥3

    High

    3.2%

    VTE prophylaxis indicated

    *Composite endpoint of symptomatic VTE or VTE-related death at 90 days. From Nendaz 2014.

    Dr. Pierre Chopard

    About the Creator

    Pierre Chopard, MD, MSc, is an associate professor at the University of Geneva, in Switzerland. He is also the chief medical officer of the Care Quality Division at Geneva University Hospitals. Dr. Chopard’s research interests include healthcare quality and risk management.

    To view Dr. Pierre Chopard's publications, visit PubMed

    About the Creator
    Dr. Pierre Chopard